Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 183

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 183
---
 the same agreement and shall become effective when one or more counterparts have been signed by each of the Parties to this Agreement and delivered to the other Parties hereto. Any such counterpart delivered as a .pdf, .tif, .gif, .jpeg or similar attachment by electronic mail or by electronic signature delivered by electronic transmission (any such delivery, “ Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. No Party hereto shall raise the use of Electronic Delivery to deliver a counterpart or signature, or the fact that any counterpart or signature was transmitted or communicated through the use of Electronic Delivery, as a defense to the formation of a contract, and each Party hereto forever waives any such defense, except to the extent such defense relates to lack of authenticity.

<div align='center'>[Signature pages follow]</div>

| 47 |

IN WITNESS WHEREOF, each of the Parties has caused this Agreement and Plan of Merger to be duly executed on its behalf as of the day and year first above written.

| COMPANY               |                   |
| MIRA                  
 PHARMACEUTICALS, INC. |                   |
| By                    | /s/               
 Erez Aminov       |
| Name:                 | Erez              
 Aminov            |
| Title:                | Chief             
 Executive Officer |

| SUBSIDIARY       |             |
| MIRAPHARM        
 ACQUISITION INC. |             |
| By               | /s/         
 Erez Aminov |
| Name:            | Erez        
 Aminov      |
| Title:           | President   |

| SKNY                  
 PHARMACEUTICALS, INC. |                 |
| By                    | /s/             
 Kelly Stackpole |
| Name:                 | Kelly           
 Stackpole       |
| Title:                | CEO             |

<div align='center'>[Signature page to Agreement and Plan of Merger]</div>

| 48 |

<div align='center'>Schedule A to Agreement and Plan of Merger</div>

At the effective time of the Merger (the “Effective Time”), each outstanding share of common stock of
SKNY, $0.0001 par value per share (“SKNY Common Stock”), will be converted into the right to receive such number of shares
of common stock of MIRA, $0.0001 par value per share (“MIRA Common Stock